KAWASAKI, Japan – August 17, 2021 –
Jiksak Bioengineering, Inc. (Jiksak) and Meiji Co., Ltd. (Meiji) today announced that they entered into a joint development agreement on July 16, 2021.
The partners will apply Jiksak’s phenotypic assay technology using human iPS-derived neurons to Meiji’s research in the food industry and will jointly develop new products to enhance health and wellness.
This agreement will allow Jiksak and Meiji to introduce a new business model in the food industry and to develop products together, with the aim of commercializing new products as soon as possible.
Jiksak Bioengineering, Inc. is a biotechnology company based in Kawasaki, Japan, which focuses on finding a cure for neurodegenerative and neuromuscular diseases, especially amyotrophic lateral sclerosis (ALS). Founded in 2017, the company has developed both synapse induction technology and a unique iPS cell-derived neural tissue analysis organoid. Jiksak’s platform provides an efficient method to actively drive drug discovery and toxicity testing.
For more information, please visit www.jiksak.co.jp/
